Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Culine

Showing results (171-180 of 185) with videos related to

Pageof 19
Sort By:
British Journal of Cancer|September 19, 2007
Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?C Massard, J-J Voigt, A Laplanche, et al.
European Journal of Cancer (Oxford, England : 1990)|February 10, 2012
Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trialM Gross-Goupil, A Fourcade, E Blot, et al.
British Journal of Cancer|August 14, 2003
Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002)R Bugat, A Bataillard, T Lesimple, et al.
The Journal of Urology|August 21, 2002
Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer CentersB Escudier, J P Droz, F Rolland, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2015
Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)M De Santis, P J Wiechno, J Bellmunt, et al.
BMC Medical Education|January 17, 2018
Choosing a career in oncology: results of a nationwide cross-sectional studyJ C Faivre, J E Bibault, A Bellesoeur, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2005
Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trialJ-P Lotz, B Bui, F Gomez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapyP Rougier, R Bugat, J Y Douillard, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 14, 2015
[Not Available]T Murez, X Durand, M Rivoire, et al.
European Journal of Cancer (Oxford, England : 1990)|November 18, 2017
Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastasesY Loriot, L Pagliaro, A Fléchon, et al.
Pageof 19

Showing results (171-180 of 185) with videos related to

Sort By:
Pageof 19
British Journal of Cancer|September 19, 2007
Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?C Massard, J-J Voigt, A Laplanche, et al.
European Journal of Cancer (Oxford, England : 1990)|February 10, 2012
Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trialM Gross-Goupil, A Fourcade, E Blot, et al.
British Journal of Cancer|August 14, 2003
Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002)R Bugat, A Bataillard, T Lesimple, et al.
The Journal of Urology|August 21, 2002
Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer CentersB Escudier, J P Droz, F Rolland, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2015
Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)M De Santis, P J Wiechno, J Bellmunt, et al.
BMC Medical Education|January 17, 2018
Choosing a career in oncology: results of a nationwide cross-sectional studyJ C Faivre, J E Bibault, A Bellesoeur, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2005
Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trialJ-P Lotz, B Bui, F Gomez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapyP Rougier, R Bugat, J Y Douillard, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 14, 2015
[Not Available]T Murez, X Durand, M Rivoire, et al.
European Journal of Cancer (Oxford, England : 1990)|November 18, 2017
Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastasesY Loriot, L Pagliaro, A Fléchon, et al.
Pageof 19